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of drugs within a particular group, such as statins, as per
large randomized clinical trials, a surrogate end point
simply cannot be used to claim a superior efﬁcacy for the
only drug (rosuvastatin) without any evidence of efﬁcacy
in terms of morbimortality.
Cost-effectiveness analysis is a very useful tool for
decision-makers to allocate properly available resources.
However, if it is not correctly conducted or it is performed
with inappropriate data, it is possible that at the end
decision-makers may make incorrect decisions with the
consequent being ineffective allocation of resources.
Therefore, we believe that rosuvastatin should demon-
strate efﬁcacy in terms of morbimortality before trying to
demonstrate cost-effectiveness.
For these reasons, we do think that this cost-
effectiveness analysis should be considered a preliminary
exploratory exercise, pending on the results of morbimor-
tality and safety of rosuvastatin from large randomized
clinical trials. Otherwise, conclusions are potentially mis-
leading for decision-makers.—Javier Soto, MD, PhD, and
Jaime Fernandez de Bobadilla, MD, Health Outcomes
Research, Medical Unit, Pﬁzer, Madrid, Spain.
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The authors reply . . .
Formulary Decision-Making Should Rely on 
the Best Available Evidence
To the Editor—Evidence of effectiveness and cost-
effectiveness is inherently dynamic in nature. Cost-
effectiveness models based on the best data available at
the time are an important contribution to evidence-based
decision-making if they reveal the likely outcomes of var-
ious scenarios and quantify the degree of uncertainty
around the apparently optimal approach. Cost-effective-
ness models also illustrate the trade-offs inherent in each
potential alternative available to the decision-maker and
should be updated as new evidence becomes available.
In 2000, The Academy of Managed Care Pharmacy
issued its ﬁrst Format for Formulary Submissions, which
provided US payers with a new tool to proactively request
clinical and economic data from health technology man-
ufacturers. The Format, which has been revised substan-
tially in recent years, is now used by health-care
organizations covering some 150 million lives in the
United States [1]. This guidance recommends that dossi-
ers for new drug products be requested by health plans
approximately 6 months before launch, and explicitly
calls for the use of economic models “to inform decisions
about the value or cost-effectiveness of pharmaceuticals,
biologics, and vaccines.” Such models are to be based on10.1111/j.1524-4733.2006.00112.x
Letter to the Editor278
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR)’s Good Research Practices—
Modeling Studies [2], which stipulate that data sources be
“clearly deﬁned and from the most recent studies.”
Our model did not extrapolate the intermediate end-
points of cholesterol reduction and National Cholesterol
Education Program Adult Treatment Panel II goal
achievement to long-term reductions in coronary heart
disease (CHD) events and mortality, for three reasons:
First, the best available head-to-head statin trials that
included  rosuvastatin  as  a  comparator—and  therefore
the time  horizon  of  our  primary  analysis—were  limited
to 1 year. Second, extrapolating to long-term outcomes
would have required us to assume a “class effect” among
the statins by employing the well-described relationship
between lipid-lowering and event reduction [3], and this
would not have changed our ﬁndings because incremental
lipid-lowering would yield incremental risk reduction.
Third, there is a precedent for publishing such “short-
term” evaluations of other statins [4–9].
We believe our analysis informs near-term decisions
about statin formulary placement in the spirit of Academy
of Manager Care Pharmacy and ISPOR guidance, using
the best data available at the time our analysis was con-
ducted in early 2005. The full conclusion of our analysis
was that rosuvastatin dominates atorvastatin, pravastatin
and branded simvastatin, and it may be considered cost-
effective compared with generic lovastatin [10]. We
acknowledged in our article that long-term trials have
documented the risk-reducing capacity of each of the
comparator products, and we recommended that deci-
sions based on our model be reconsidered when long-term
effectiveness and safety data become available for
rosuvastatin.
The strategy tacitly advocated by Drs Soto and Boba-
dilla is to use only older statins until long-term rosuvas-
tatin trials are completed. Our analysis quantiﬁed the
trade-offs associated with that strategy. The results indi-
cate that the opportunity cost could be substantial due to
the lower average cost and greater LDL-C lowering
potential of rosuvastatin compared to atorvastatin, prav-
astatin, and simvastatin.
Our analysis did assume that adverse event rates would
be similar across the class, based on clinical trial evidence
available at the time. The recent article by Alsheikh-Ali
and colleagues [11] does not conclude that spontaneous
adverse event reports (AERs) are indicative of actual rates,
and the authors acknowledge that external factors such as
media coverage and available doses may explain differ-
ences in spontaneous AER. After careful review of the
same AERs, the Food and Drug Administration concluded
that “Crestor (rosuvastatin) does not pose a risk of muscle
toxicity greater than that of other approved statins. With
respect to renal toxicity, there is no convincing evidence
that Crestor poses a risk of serious renal injury [12].” We
did not include C-reactive protein (CRP) reduction as a
measure  of  efﬁcacy  in  our  analysis  because  data were
not available for rosuvastatin at the time. Although the
importance of CRP and other inﬂammatory markers as
independent risk factors for CHD is currently a topic of
intense study, current treatment guidelines do not identify
CRP as a target of therapy [13,14] and statins are not indi-
cated for the reduction of CRP. The objective of treatment
remains LDL-C reduction [13].
In conclusion, we encourage managed care decision-
makers to consider carefully and critically all of the evi-
dence available for any product at the time of its launch.
The most valuable decision tools are those that illustrate
the risks, beneﬁts, and trade-offs of potential decisions,
including the opportunity cost of waiting for more data.
Information available at the time of launch will inevitably
be incomplete, but it can also be profoundly helpful to
decision-makers who interpret the results in light of the
limitations and commit to updating decisions when new
data warrant.—Joshua S. Benner PharmD, ScD, Timothy
W. Smith, David Klingman, PhD, Jonothan C. Tierce
CPhil, ValueMedics Research, Falls Church, VA, USA; C.
Daniel Mullins PhD, University of Marlyand, Baltimore,
MD, USA; Ned Pethick, AstraZeneca, Wilmington, DE,
USA; and John C. O’Donnell PhD, AstraZeneca, Mac-
clesﬁeld, UK.
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